This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
—It appears that in certain quarters the attitude is taken that the local anesthetic sold as procain is not identical with that marketed as novocain. The Subcommittee on Synthetic Drugs of the National Research Council believes it important that this misunderstanding should be corrected and hence offers the following explanation:The monohydrochlorid of para-amino-benzoyldiethyl-amino-ethanol, which was formerly made in Germany by the Farbwerke, vorm. Meister, Lucius and Bruening, Hoechst A. M., and sold under the trademarked name "Novocaine," is now manufactured in the United States. Under the provisions of the Trading with the Enemy Act, the Federal Trade Commission has taken over the patent that gave monopoly for the manufacture and sale of the local anesthetic to the German corporation, and has issued licenses to American concerns for the manufacture of the product. This license makes it a condition that the product first introduced under the proprietary
Stieglitz J. PROCAIN AND NOVOCAIN IDENTICAL. JAMA. 1918;70(25):1969. doi:10.1001/jama.1918.02600250069020
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.